A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma

Inclusion Criteria: * 1\. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * 2\. Male/female participants who are at least 18 years of age on the day of signing informed consent. * 3\. Histologically confirmed diagnosis of resectable AJCC (8th edition) Stage IIIB, IIIC or IIID cutaneous or unknown primary melanoma (except for any in-transit or satellite metastases) will be enrolled in this study. Note: * At baseline, patients may have a primary melanoma in addition to nodal disease. * At baseline, there must be sufficient nodal +/- primary disease which is amenable to multiple excision or core biopsies biopsies. * "Resectable" disease is defined as having no significant vascular, central nervous system or bony involvement. Only cases where a complete surgical resection leading to tumour free margins and which is safely achieved is considered "resectable". * 4\. Have measurable disease based on RECIST version 1.1 criteria: ≥ 10mm in the longest diameter for primary (if applicable) lesions and ≥ 15mm in the shortest diameter for lymph nodes. * 5\. Have provided a newly obtained core or excisional biopsy of an affected lymph node lesion which has been not previously irradiated. Archival tissue from the primary melanoma (if applicable) will also be collected, if available, but is not a requirement for study entry. * 6\. Able to swallow and retain oral medication. * 7\. A male participant must agree to us…